A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-Pd-L1 Antibody) in Combination With Paclitaxel Compared With Placebo With Paclitaxel for Patients With Previously Untreated Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 11 Jan 2019
At a glance
- Drugs Atezolizumab (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms IMpassion131
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 08 Sep 2017 Trial design presented at 42nd European Society for Medical Oncology Congress.
- 12 Jun 2017 Status changed from not yet recruiting to recruiting.